Exhaled Breath Condensate Biomarkers in CARAS

NCT ID: NCT06573450

Last Updated: 2024-08-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

270 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-01

Study Completion Date

2025-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To explore the differences in the expression of biomarkers in different sample types between the healthy population and different subgroups of the disease, and to screen for potential biomarkers in a more simple, direct and objective way. To screen the biomarkers that can be identified by CARAS Chinese medicine symptoms and different stages, and to provide a reference basis for individualised diagnosis and treatment of the disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Combined Allergic Rhinitis and Asthma Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

acute exacerbation CARAS

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

questionnaire survey

Intervention Type OTHER

subjects fill out questionnaires

chronic persistence CARAS

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

questionnaire survey

Intervention Type OTHER

subjects fill out questionnaires

clinical control CARAS

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

questionnaire survey

Intervention Type OTHER

subjects fill out questionnaires

acute exacerbation BA

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

questionnaire survey

Intervention Type OTHER

subjects fill out questionnaires

chronic persistence BA

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

questionnaire survey

Intervention Type OTHER

subjects fill out questionnaires

clinical control BA

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

questionnaire survey

Intervention Type OTHER

subjects fill out questionnaires

intermittent AR

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

questionnaire survey

Intervention Type OTHER

subjects fill out questionnaires

persistent AR

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

questionnaire survey

Intervention Type OTHER

subjects fill out questionnaires

healthy individuals

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

questionnaire survey

Intervention Type OTHER

subjects fill out questionnaires

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

questionnaire survey

subjects fill out questionnaires

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with AR, BA and CARAS who meet the Western medical diagnostic criteria;
* Chinese medical evidence consistent with lung qi deficiency evidence, phlegm-heat congestion of the lung evidence, or wind-heat offending the lung evidence;
* Age 18 to 80 years;
* Voluntarily accepted the study and signed an informed consent form;
* Not participated in other clinical studies within 1 month before enrollment.

Exclusion Criteria

* Patients with combined vasomotor rhinitis and eosinophilic non-allergic rhinitis, other non-allergic rhinitis diseases that can cause symptoms such as nasal congestion and runny nose;
* Patients who are participating in other drug trials;
* Patients with a combination of other serious systemic diseases;
* Pregnant or lactating women;
* Patients with confusion, disorders of consciousness, dementia, and various psychiatric disorders.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Henan University of Traditional Chinese Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The First Affiliated Hospital of Henan University of Chinese Medicine

Henan, Zhengzhou, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yang Xie

Role: CONTACT

13526621325

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yang Xie, Ph.D

Role: primary

+8613526621325

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EBC biomarkers in CARAS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Asthma Biomarker Study
NCT02392481 COMPLETED
A Phase Ib Study of RC1416 Injection
NCT06911866 RECRUITING PHASE1
TNF Alpha in Refractory Asthma
NCT00276029 COMPLETED NA